Core Viewpoint - The Chinese eye care industry is undergoing significant transformation driven by the dual forces of rising public demand for eye health and technological innovation [1][2] Group 1: Industry Transformation - The eye care industry is leveraging advanced technologies such as artificial intelligence, genetics, and stem cells to enhance eye health services towards intelligent, precise, and inclusive solutions [1] - The establishment of a nationwide eye health service network through a franchise model aims to provide high-quality eye care services to a broader population, promoting professionalization and standardization within the industry [1] Group 2: Conference Highlights - The 2025 China Eye Care Operation and Development Conference featured four main discussion panels focusing on industry trends, technological innovations, digital transformation, and operational management [2] - Experts emphasized the importance of visual health as a fundamental aspect of overall health, aligning with the "Healthy China" strategy, particularly in areas like myopia prevention in children and elderly eye health services [2] Group 3: Talent Development - The launch of the "Light of Vision" talent training program aims to build a comprehensive talent pipeline across the eye care industry, supported by authoritative resources from the National Health Commission and professional expertise from Liaoning He Eye Hospital [2] Group 4: Specialized Activities - Various specialized activities, including roundtable discussions and satellite meetings, were held to explore topics such as industry transformation practices and innovative models for myopia prevention [3] - Participating companies showcased their latest products and technological advancements during the conference [3]

Core Viewpoint - The company, He Shi Eye Hospital, is facing significant challenges, including a substantial decline in stock price and ongoing shareholder reduction pressures, amid a competitive landscape in the ophthalmology industry [1][3][7]. Company Summary - He Shi Eye Hospital's major shareholder, Advanced Manufacturing Industry Investment Fund, plans to reduce its holdings by up to 3.1061 million shares, representing 2% of the total share capital, marking the second attempt for a similar reduction [3]. - The company's stock price has dropped over 60% from its historical peak, closing at 21.82 yuan per share as of July 2, 2025 [1][3]. - Since its establishment in 1995, He Shi Eye Hospital has expanded from a small clinic to a group-based ophthalmology service provider, currently operating 127 service institutions as of the end of 2024 [6]. Financial Performance - In 2022, He Shi Eye Hospital reported a revenue of 9.55 billion yuan, a slight decrease of 0.74% year-on-year, with a net profit of 0.33 billion yuan, down 61.55% [7]. - The financial situation worsened in 2024, with revenue declining by 7.56% to 10.96 billion yuan and a net loss of 0.2739 billion yuan, marking a 143.11% year-on-year decline [7][8]. - Compared to competitors like Aier Eye Hospital, which maintained a revenue growth rate of around 20%, He Shi Eye Hospital has experienced negative growth since its IPO [7][9]. Industry Context - The ophthalmology market in China is undergoing significant changes, with the number of private eye hospitals increasing from 890 to 1,609 between 2019 and 2023, reflecting a compound annual growth rate of 15.4% [9]. - He Shi Eye Hospital's main business segments, including cataract, optical, and refractive services, have all faced revenue declines due to increased competition from larger players [9][10]. - The industry is also impacted by policy changes, such as the reform of medical insurance payment methods and centralized procurement of medical supplies, which have reduced procurement costs by 60% but also compressed profit margins [10].

Group 1 - Aike Cyber (688719.SH) shareholders Dachen Chuangtong and Dachen Chuanghong reduced their holdings by 2,298,151 shares, accounting for 1.99% of the total share capital, and did not complete the planned reduction [1] - Benchuan Intelligent (300964.SZ) controlling shareholder Dong Xiaojun reduced his holdings by 355,787 shares, accounting for 0.4582% of the total share capital, bringing his shareholding down to 21.64% [1] - Changlian Co., Ltd. (603648.SH) completed its reduction plan by selling 3,624,050 shares, which is 1% of the total share capital [1] Group 2 - Chuan Yi Technology (002866.SZ) controlling shareholder Zou Weimin and his concerted party reduced their holdings, with Zou's shareholding dropping to 48.53% [2] - Daoshi Technology (300409.SZ) controlling shareholder Rong Jihua plans to reduce his holdings by up to 15,416,611 shares, accounting for 1.97% of the total share capital [2] - Electric Alloy (300697.SZ) completed its reduction plan by selling 2,741,390 shares, which is 0.63% of the total share capital [2] Group 3 - Fujirei (688272.SH) shareholders Suzhou Kongkong, Suzhou Zhaorong, and Shanghai Zhaoren reduced their holdings by 1,215,618 shares, 1,463,490 shares, and 44,944 shares, accounting for 1.60%, 1.93%, and 0.06% of the total share capital respectively [3] - Gaoweida (300465.SZ) controlling shareholder Yingtan Yinggao Investment Consulting Co., Ltd. reduced its holdings by 4,261,700 shares, accounting for 0.96% of the total share capital, bringing its shareholding down to 22.00% [3] - Haizheng Materials (688203.SH) shareholder Sinopec Capital plans to reduce its holdings by up to 3,525,600 shares, accounting for 1.74% of the total share capital [3] Group 4 - Hangyu Micro (300053.SZ) shareholder Yan Jun reduced his holdings by 3,930,000 shares, accounting for 0.56% of the total share capital [4] - He Shi Eye Hospital (301103.SZ) shareholder Advanced Manufacturing Industry Investment Fund plans to reduce its holdings by up to 3,106,074 shares, accounting for 2% of the total share capital [4] - He Yuan Gas (002971.SZ) shareholder Baishide Chuangye completed its reduction plan by selling 854,064 shares, which is 0.415% of the total share capital [4] Group 5 - Huaren Health (301408.SZ) shareholder Saifu Investment reduced its holdings by 2,107,696 shares, accounting for 0.53% of the total share capital [5] - Jiangsu Boyun (301003.SZ) shareholder Gong Wei reduced his holdings by 1,558,900 shares, accounting for 1.57% of the total share capital [5] - Jeya Co., Ltd. (301108.SZ) shareholders Mingyuan Fund and its concerted party did not reduce their holdings, and the reduction plan period expired [5] Group 6 - Longxin General (603766.SH) directors plan to reduce their holdings by up to 350,000 shares and 100,000 shares, accounting for 0.0170% and 0.0049% of the total share capital respectively [6] - Ruchuang Micro-Nano (688002.SH) shareholder Li Weicheng plans to reduce his holdings by up to 8,000,000 shares, accounting for 1.75% of the total share capital [6] - Shilan Micro (600460.SH) shareholder Luo Huabing plans to reduce his holdings by up to 500,000 shares, accounting for 0.03005% of the total share capital [6] Group 7 - Tongfu Microelectronics (002156.SZ) shareholder National Integrated Circuit Industry Investment Fund reduced its holdings by 15,175,969 shares, accounting for 1% of the total share capital [7] - Wangzi New Materials (002735.SZ) controlling shareholder Wang Jinjun reduced his holdings by 9,717,874 shares, accounting for 2.54% of the total share capital [7] - Xingye Co., Ltd. (603928.SH) shareholder Shen Genzhen reduced his holdings by 2,620,000 shares, accounting for 1.00% of the total share capital [7] Group 8 - Yikang Co., Ltd. (301085.SZ) controlling shareholder concerted party reduced its holdings by 633,700 shares, accounting for 0.73% of the total share capital [8] Group 9 - Yiming Pharmaceutical (002826.SZ) major shareholder Zhou Zhan reduced his holdings by 3,586,777 shares, accounting for 1.88% of the total share capital [9] - Yiming Pharmaceutical (002826.SZ) director Xi Ke reduced his holdings by 283,862 shares, accounting for 0.15% of the total share capital [9] - Youyan Powder Materials (688456.SH) concerted party reduced its holdings by 1,030,000 shares, accounting for 0.99% of the total share capital [9] Group 10 - Zhongma Transmission (603767.SH) directors plan to reduce their holdings through block trading and centralized bidding [10] - Zhongqi Co., Ltd. (301215.SZ) shareholder Jiangsu Yueda Group did not reduce its holdings, and the reduction plan period expired [10]

Company Announcements - Jihua Group's existing product system does not involve brain-computer interface related fields [1] - Prit's plan to invest 1 billion yuan to build a plastic modification materials headquarters and R&D manufacturing base in South China [1][2] - Lian De Equipment won a contract worth 157 million yuan for BOE's 8.6 generation AMOLED production line project [1][2] - Jiadu Technology plans to issue shares (H-shares) overseas and list on the Hong Kong Stock Exchange [1][2] - Longdi Group intends to acquire no more than 20.1667% equity in Jujia Technology [1][4] - New Zhonggang plans to repurchase shares worth 40 million to 80 million yuan [1][4] - Xiaogoods City expects a net profit increase of 12.57% to 17.40% in the first half of the year [1][4] - Sinopec Capital plans to reduce its holdings by no more than 3.5256 million shares in Haizheng Materials through block trading [1][4] - Lihua Co., Ltd. intends to reduce its holdings by no more than 3.00% [1][4] - Zhimin Da plans to raise no more than 213 million yuan through a private placement [1][5] - Xiangtong Co. plans to issue corporate bonds not exceeding 4 billion yuan [1][5] Performance Forecasts - Hanyu Pharmaceutical expects a half-year profit of 142 million to 162 million yuan, turning a profit compared to the previous year [4] - Taotao Automotive anticipates a net profit increase of 70.34% to 97.81% in the first half of the year [4] - Weichai Heavy Machinery expects a net profit increase of 40% to 60% in the first half of the year [4] Shareholding Changes - Lihua Co., Ltd.'s actual controller Cheng Lili and his concerted actors plan to reduce their holdings by no more than 3.00% [4] - He Shi Eye Hospital's Advanced Manufacturing Fund plans to reduce its holdings by no more than 2% [4] - Haitan Ruisheng's shareholder He Lin and his concerted actors plan to reduce their holdings by no more than 2.9463% [4] - Sinopec Capital plans to reduce its holdings by no more than 3.5256 million shares in Haizheng Materials [4] Other Announcements - Zhimin Da plans to raise no more than 213 million yuan through a private placement [5] - Yuyuan Co. plans to issue corporate bonds not exceeding 40 billion yuan [5] - Jinhongshun has terminated the planning of a major asset restructuring [5]

证券代码：301103 证券简称：何氏眼科 公告编号：2025-021 辽宁何氏眼科医院集团股份有限公司 关于持股 5%以上股东减持股份预披露公告 持股 5%以上股东先进制造产业投资基金（有限合伙）保证向本公司提供的信 息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 辽宁何氏眼科医院集团股份有限公司（以下简称"公司、上市公司"）于近 日收到持股 5%以上股东先进制造产业投资基金（有限合伙）（以下简称"先进制 造基金"）出具的《关于股份减持计划的告知函》，先进制造基金计划自本公告披 露之日起十五个交易日后的三个月内（即 2025 年 7 月 22 日至 2025 年 10 月 21 日期间），通过证券交易所集中竞价和大宗交易方式减持公司股份合计不超过 3,106,074股（占公司剔除回购专用证券账户中股份数量后的总股本比例的2%）。 若计划减持期间公司有派息、送股、转增股本、配股等除权除息事项，上述拟减 持股份数量将相应进行调整，但减持股份占扣除公司回购股份数后的总股本的比 例不变。现将具体情况公告如下： 一、股东的基 ...

Group 1 - The Shanghai Cooperation Organization (SCO) School Management Training Program aims to enhance understanding of China's higher education practices in talent cultivation, industry-academia integration, innovation, and digital healthcare among participants from SCO member countries [1][2] - Since 2012, Shenyang Normal University has successfully conducted 29 training programs, training 756 participants from 62 countries, including Russia, Uzbekistan, Kazakhstan, South Africa, and Lesotho [2] - The program is a collaboration between Shenyang Normal University, He Eye Hospital, and Liaoning He Eye Medical College, leveraging their strengths in international education and ophthalmology [2][3] Group 2 - He Eye Hospital, as an international ophthalmology training institution, aims to create an international, efficient, and innovative training model to cultivate ophthalmologists with international diagnostic and treatment standards [3] - The training program is part of China's Belt and Road Initiative, providing capacity building for ophthalmologists from Africa, Asia, and Latin America, sharing China's experience in blindness prevention [3] - The opening of the training program is significant for promoting educational cooperation among SCO countries and enhancing the management capabilities of higher education institutions [3]

Group 1 - The "Healthy Liaoning Colorful Vision 2025 National Eye Care Public Welfare Action" was launched in Shenyang, aiming to promote eye health awareness and establish a comprehensive eye health service ecosystem [2] - The initiative includes the release of the "2025 National Eye Care Lifestyle Guide," which provides localized eye care solutions for different demographic groups, including children, youth, middle-aged, elderly, and diabetic patients [2] - The "AI Smart Prevention and Treatment Month for Diabetic Eye Diseases" was also initiated, utilizing AI retinal cameras for eye health screenings across multiple locations in Liaoning province [2] Group 2 - The "Blue Ribbon Public Welfare Action for Exam Candidates" was launched to protect the eye health of students during the important exam season, with medical service stations set up at various exam sites in Liaoning [3] - The company aims to leverage this initiative to collaborate with authoritative media and community healthcare networks, promoting public awareness, scientific education, and AI-driven healthcare solutions [3] - The goal is to create a new ecosystem for smart eye health management, making communities the first line of defense for public health and utilizing technological innovations to benefit the public [3]

Group 1 - The core viewpoint of the news is that He Eye Hospital's stock has seen a recent increase, closing at 23.33 yuan with a 3.32% rise, while its market-to-book ratio has reached a new low in 112 days at 1.93, with a total market value of 3.687 billion yuan [1] - The company has experienced a net inflow of main funds amounting to 5.7969 million yuan on June 5, with a total inflow of 18.9978 million yuan over the past five days, indicating a positive trend in fund flow [1] - He Eye Hospital specializes in personalized and intelligent eye health management services, offering products such as refractive surgery, cataract treatment, vitreoretinal treatment, and other eye disease treatments [1] Group 2 - The latest financial report for the first quarter of 2025 shows that the company achieved an operating income of 291 million yuan, representing a year-on-year increase of 2.35%, and a net profit of 32.5319 million yuan, up 12.27% year-on-year, with a gross profit margin of 43.80% [1] - In comparison to industry averages, He Eye Hospital's price-to-earnings (PE) ratios are significantly lower, with a trailing PE of -154.63 and a static PE of -134.56, while the industry average PE is 40.82 [2] - The company's market value stands at 3.687 billion yuan, which is lower than the industry median of 5.893 billion yuan [2]

中原证券股份有限公司 关于辽宁何氏眼科医院集团股份有限公司 三、培训效果情况 本次持续督导培训的工作过程中，何氏眼科及参会人员给予了积极配合。本 次培训加强了公司董事、监事、高级管理人员等人员对募集资金使用等相关法律 法规的理解，促使上述对象增强法制观念和合规意识。本次培训有助于进一步提 升何氏眼科的规范运作水平。 （以下无正文） （此页无正文，为《中原证券股份有限公司关于辽宁何氏眼科医院集团股份有 限公司 2025 年持续督导培训情况的报告》之签字盖章页） 保荐代表人：___________ ____________ 2025 年持续督导培训情况的报告 根据《证券发行上市保荐业务管理办法》《深圳证券交易所创业板股票上市 规则》《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》《深圳 证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等相关 法律、法规和规范性文件的规定，中原证券股份有限公司（以下简称"中原证券"、 "保荐机构"）作为辽宁何氏眼科医院集团股份有限公司（以下简称"公司"或"何 氏眼科"）首次公开发行并在创业板上市的保荐机构，对公司董事、监事、高级 管理人员等相关人员 ...

Group 1 - The core viewpoint of the articles highlights the advancement in the diagnosis and treatment of amblyopia through genetic testing and innovative therapies, particularly the use of perceptual learning training [1][2] - The introduction of genetic testing allows for more accurate diagnosis by identifying pathogenic gene mutations, which can lead to more effective treatment strategies [1][2] - The perceptual learning training technique utilizes the brain's plasticity to improve visual processing pathways, enhancing treatment outcomes for patients with amblyopia and related conditions [2] Group 2 - He Eye Hospital has been committed to technological innovation and collaboration with strategic partners to advance eye health, focusing on gene therapy, stem cell regeneration, and smart ophthalmic equipment [3] - The company aims to integrate cutting-edge technology with healthcare data to create a comprehensive ecosystem for eye health, aligning with national health strategies [3] - The strategic goal of He Eye Hospital is to build a "Smart City of Light," leveraging its unique advantages in the eye health industry [3]